Crossroads Orthopedics, LLC
$36.8K 306 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Phadia AB
Phadia AB reported $36,873.10 across General Payments, Research, and Ownership to 14 physicians and teaching hospitals across 15 transactions.
- $36.9K Below-median payer
- All-tracks total
- 15 Below-median volume
- Transactions
- 14 Below-median reach
- Recipients
- +$10.4K
- General Payments vs PY2023
Phadia AB reported $36,873.10 across all CMS Open Payments tracks (General + Research + Ownership) to 14 physicians and teaching hospitals in Program Year 2024 - ranking #1420 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $11,873.10, averaging $2.6K per recipient.
How Phadia AB's $36.9K all-tracks total breaks down
Phadia AB's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer phadia-ab Phadia AB
$36.9K · #1420/1,925 · 0.0% industry · PY2024
- TOT $36.9K
- RANK #1420
- SHARE 0.0%
- TXN 15
- RCP 14
- CAT 2
- GEN $11.9K
- ΔGEN +$10.4K
- TOP1 35.6%
- PY 2024
Volume peers
Nearest volume peer: Crossroads Orthopedics, LLC ($36.8K)
Phadia AB sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Phadia AB's CMS-reported General Payments increased by $10.4K (+691.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PHADIA ABPY2023: PHADIA ABPY2024: Phadia AB. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,500.00
- PY2024
- $11,873.10
What the Data Shows for Phadia AB
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Phadia AB, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 2 general-payment categories charted below, "Travel and Lodging" is the largest at $11.7K across 12 transactions, 98.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 2 types of general payments, Phadia AB's largest category was "Travel and Lodging" at $11.7K - 98.8% of General Payments.
How Phadia AB divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $11.7K | 12 | 98.8% |
| Food and Beverage | $144.83 | 2 | 1.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $11,873.10 (100.0%) of $11,873.10 in this company's General Payments records across 4 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Phadia AB
The five named recipients with the highest reported General Payments from this company
- 1
Lee Hilborne
$4,226.34 across 3 reported transactions
- 2
Renee Sullivan
$3,202.98 across 3 reported transactions
- 3
Holly Hilsenbeck
$3,002.61 across 3 reported transactions
- 4
Nathan Richards
$1,441.17 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Phadia AB ranks #1420 of 1,925 by total payments (bottom 26% by spend) but is notably more concentrated than that alone would suggest -- #601 of 1,838 by HHI (top 33% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Leadiant Biosciences, Inc. : $6.7K total payments, HHI 2813
- SRS Medical Systems, Inc. : $54.6K total payments, HHI 2811
- Wardlow Enterprises : $3.5K total payments, HHI 2803
- Stability Biologics, LLC : $235.6K total payments, HHI 2790
- Elekta Instrument AB : $354.2K total payments, HHI 2789
- Masimo Corporation : $2.6M total payments, HHI 2786
- Phadia AB (this company) : $11.9K total payments, HHI 2782
- Daiichi Sankyo Europe GmbH : $77.3K total payments, HHI 2769
- Pramand LLC : $22.8K total payments, HHI 2763
- Cleerly, Inc. : $157.5K total payments, HHI 2760
- Biodynamik, Inc : $23.6K total payments, HHI 2759
- Blue Sky Bio, LLC : $314.2K total payments, HHI 2746
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Phadia AB's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Phadia AB.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Phadia AB.
Showing 6 of 1,924 companies with CMS-reported payment data.
Conetic Solutions, Inc.
$36.7K 474 recipients
Compare payment profiles
Nucletron B.V.
$36.7K 4 recipients
Compare payment profiles
Sensible Medical Innovations Inc
$37.1K 35 recipients
Compare payment profiles
Mauna Kea Technologies, Inc.
$36.6K 879 recipients
Compare payment profiles
Clinical Technology, Inc
$36.5K 47 recipients
Compare payment profiles
Put this to use
Phadia AB ranks #1420 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Phadia AB. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.